MBX Biosciences, Inc. Common Stock
NASDAQ:MBXBiotechnology
-$0.64 today
- Market cap
- $2.65B
- Beta
- 0.75
- P/E (TTM)
- -22.0
- EPS (TTM)
- -$1.86
Volume 0.73M
Average 0.65M
MBX Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
MBX Biosciences, Inc. Common StockNASDAQ: MBX
Investing Cash Flow · Q3 FY2026 · quarter ended Sep 2026
Investing cash flow grows, but more slowly than its trailing trend
Q3 FY2026 investing cash flow of $42.83M rose 151.1% year over year, behind the +635.5% change in trailing-twelve-month investing cash flow. Sequentially, it rose 46.6% from the prior quarter. Over 3 fiscal years it compounded at +94.3% a year.
Context
- Investing cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +151.1% toward the trailing-twelve-month pace of +635.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (83.71M) USD
- Year-over-year change
- +47.9%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (83.71M) | +47.9% |
| FY2024 | 2024-12-31 | (160.6M) | -419.3% |
| FY2023 | 2023-12-31 | (30.93M) | -171.0% |
| FY2022 | 2022-12-31 | (11.41M) | — |
Investing Cash Flow vs competitors
How MBX compares with its peers on the latest reported figures
- Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +635.5% is the highest of 8, against a peer median of +158.3%.
- Over three fiscal years its annual growth of +94.3% compares with a peer median of +21.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
KLRAKailera Therapeutics, Inc. | FY2025 | $492.6M USD | — | — | — |
| LTM Jun 2026 | $399.26M USD | +188.8% | +84.1% | — | |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | $155.03M USD | +635.5% | +94.3% | — |
| LTM Mar 2026 | $131.06M USD | -2272.1% | +21.8% | 364061.1% | |
| LTM Sep 2026 | $85.31M USD | +158.3% | — | 30.4% | |
| LTM Mar 2026 | $37.34M USD | -137.6% | -43.5% | — | |
| LTM Sep 2026 | €15M EUR | +173.9% | — | 1.2% | |
| LTM Mar 2026 | $1.01M USD | -104.1% | — | 0.3% | |
| LTM Mar 2026 | $550K USD | +268.2% | — | — | |
| Peer median (excluding MBX) | — | +158.3% | +21.8% | 15.8% | |
Competitors are the stored peer set for MBX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (26.14M) | (32.56M) | (61.92M) | (86.97M) |
| Depreciation & Amortization | 56K | 157K | 244K | 248K |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 306K | 2.04M | 5.22M | 8.68M |
| Change in Working Capital | 1.29M | (735K) | 4.6M | 1.58M |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 671K | 412K | 3.93M | (2.46M) |
| Other Working Capital | 619K | (1.15M) | 670K | 4.03M |
| Other Non-Cash Items | 1.36M | (880K) | (2.82M) | (3.48M) |
| Operating Cash Flow | (23.12M) | (31.98M) | (54.68M) | (79.95M) |
| Capital Expenditures | (441K) | (129K) | (874K) | (1.93M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (20.22M) | (63.8M) | (239.47M) | (358.15M) |
| Sales of Investments | 9.25M | 33M | 79.75M | 267.87M |
| Other Investing Activities | 0 | 0 | 0 | 8.5M |
| Investing Cash Flow | (11.41M) | (30.93M) | (160.6M) | (83.71M) |
| Debt Repayment | 10M | 0 | 0 | 0 |
| Common Stock Issued | 30K | 739K | 174.54M | 189.59M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | (428K) | (30K) | (3.94M) | 0 |
| Financing Cash Flow | 46.06M | 69.22M | 234.1M | 189.59M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 11.53M | 6.31M | 18.83M | 25.94M |
| Free Cash Flow | (23.56M) | (32.11M) | (55.56M) | (81.88M) |
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
Intrinsic Alpha fair value
Locked
Current Price
$53.42
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.